A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Preceded by a Dose-finding, Lead-in Phase
Phase of Trial: Phase III
Latest Information Update: 18 Mar 2019
Price : $35 *
At a glance
- Drugs Momelotinib (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sierra Oncology
- 30 Jul 2018 Results published in the Investigational New Drugs
- 21 Mar 2017 Planned End Date changed from 1 Nov 2017 to 1 Apr 2017.
- 27 Feb 2017 Planned End Date changed from 1 Jun 2017 to 1 Nov 2017.